S-1: Cingulate Inc. Files for Resale of 1,000,000 Shares of Common Stock by Lincoln Park Capital

Cingulate Inc. has filed a registration statement for the resale of up to 1,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC, as part of a previously established purchase agreement.

Summary

• Cingulate Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 1,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC.
• These shares are related to a purchase agreement dated April 24, 2023, where Cingulate may sell shares to Lincoln Park from time to time.
• Cingulate will not receive any proceeds from the resale of shares by Lincoln Park, but may receive up to $10,539,047.82 from its sale of Purchase Shares to Lincoln Park.
• The price Lincoln Park pays for the shares will depend on the timing of sales and the trading price of Cingulate's common stock.
• As of August 16, 2024, Cingulate had 1,729,419 shares of common stock issued and outstanding.
• The last reported sale price of Cingulate's common stock on Nasdaq on August 16, 2024, was $17.69 per share.
• Cingulate is an emerging growth company and is subject to reduced public company reporting requirements.
• On August 9, 2024, Cingulate effected a 1-for-12 reverse stock split.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily outlining the terms of a stock resale agreement. While it provides potential funding for the company, it also highlights risks associated with dilution and market price volatility.

Positives

• Cingulate has access to potential funding of up to $10,539,047.82 through the purchase agreement with Lincoln Park.
• The company retains control over the timing and amount of sales of common stock to Lincoln Park.
• The Purchase Agreement can be terminated by Cingulate at any time without penalty.

Negatives

• Existing stockholders will experience dilution as a result of the issuance of common stock to Lincoln Park.
• The market price of Cingulate's common stock could decrease due to sales of shares by Lincoln Park.
• The company's reliance on sales to Lincoln Park may make it more difficult to secure alternative financing in the future.

Risks

• Investment in Cingulate's securities is highly speculative and involves a high degree of risk.
• The actual number of shares sold to Lincoln Park and the gross proceeds are uncertain.
• The terms of the Purchase Agreement limit the amount of shares that can be issued to Lincoln Park.
• Investors who buy shares at different times will likely pay different prices.
• The sale or issuance of common stock to Lincoln Park may cause dilution and decrease the price of the common stock.

Future Outlook

Cingulate may sell shares to Lincoln Park from time to time over a 36-month period, depending on market conditions and the company's funding needs. The company intends to use any proceeds from the sale of shares to Lincoln Park for continued research and development and commercialization activities of CTx-1301, and for working capital, capital expenditures and general corporate purposes, including investing further in research and development efforts.

Industry Context

The document does not provide specific industry context beyond mentioning the ADHD treatment market.

Stakeholder Impact

• Existing stockholders will experience dilution.
• The market price of Cingulate's common stock could be affected by sales of shares by Lincoln Park.
• The company's ability to fund its operations and research and development efforts could be impacted by the availability of funding from Lincoln Park.

Next Steps

• The SEC must declare the registration statement effective.
• Lincoln Park may then offer and sell the shares of common stock from time to time.
• Cingulate may elect to sell shares to Lincoln Park under the Purchase Agreement, depending on market conditions and funding needs.

Key Dates

Keywords

common stock, Lincoln Park Capital, registration statement, resale, purchase agreement, Cingulate Inc., financing, dilution, shares, securities